ADC Therapeutics SA filings document the regulatory record of a Swiss commercial-stage biotechnology company with common shares listed on the New York Stock Exchange. Its Form 8-K reports cover operating results, preliminary financial information, Regulation FD presentations, clinical data updates for ZYNLONTA studies, and material agreements including amendments to royalty financing arrangements.
Proxy materials describe annual general meeting matters under Swiss law, including approval of annual and consolidated financial statements, compensation report votes, discharge of directors and executive committee members, board and compensation committee elections, auditor matters and share capital governance. The filings also identify the company’s registered common shares, par value and exchange listing.
ADC Therapeutics reported that its Chief Financial Officer, Jose Carmona, received an award of 203,700 restricted stock units on June 30, 2026. These RSUs vest on the earlier of June 30, 2027 or certain qualifying termination events, assuming continued employment. Each RSU converts into one common share, bringing his direct holdings to 938,076 common shares after the award.
MALLIK AMEET reported acquisition or exercise transactions in this Form 4 filing.
ADC Therapeutics SA reported that Chief Executive Officer Ameet Mallik received an equity compensation award in the form of 675,000 restricted stock units on June 30, 2026. These RSUs vest upon the earlier of June 30, 2027 or certain qualifying terminations of employment, conditioned on continued service. Following the grant, Mallik directly holds 2,121,769 common shares.
ADC Therapeutics approved one-time retention awards for key executives to encourage them to stay with the company. On June 30, 2026, the board, advised by its independent compensation consultant, granted cash bonuses payable on or about July 15, 2026 and restricted stock units (RSUs) that vest after one year or upon certain terminations.
CEO Ameet Mallik will receive a cash incentive of $1,795,500 and 675,000 RSUs, CFO Jose Carmona will receive $541,842 and 203,700 RSUs, and Chief Medical Officer Mohamed Zaki will receive $568,974 and 213,900 RSUs. Executives must generally remain employed through June 30, 2027 to keep the cash awards and for RSUs to vest, except if they are terminated without cause or resign for good reason.
ADC Therapeutics is implementing a strategic reorganization centered on its ZYNLONTA franchise, including a global workforce reduction of approximately 17 percent. This move is tied to the expected completion of the LOTIS-5 and LOTIS-7 trials and to operational efficiencies.
The company expects the reorganization to generate annualized estimated cost savings of about $10 million, while incurring one-time pre-tax charges of roughly $3 million for severance, benefits and related termination costs, mostly in the second quarter of 2026. Management states it has an expected cash runway at least into 2028 and is preparing for an August 2026 pre-sBLA meeting with the FDA for LOTIS-5, with an sBLA submission planned for the fourth quarter of 2026 and full LOTIS-7 data anticipated by the end of 2026.
ADC Therapeutics SA director Robert Azelby reported routine equity compensation and related tax withholding. On June 1, 2026, he received a grant of 45,000 Common Share RSUs under the 2019 Equity Incentive Plan for his service as a director, vesting at the earlier of one year from grant or the 2027 annual meeting. On June 3, 2026, 12,600 Common Shares were withheld by the company at $3.08 per share to satisfy tax obligations from previously vested RSUs. After these transactions, Azelby directly holds 112,805 Common Shares.
ADC Therapeutics SA director Ron Squarer reported routine equity compensation and related tax withholding. On June 1, 2026, he received an annual grant of 45,000 restricted stock units for board service under the 2019 Equity Incentive Plan, with each RSU representing one common share upon vesting.
On June 3, 2026, 15,196 common shares were withheld by the company to cover his tax obligations when previously granted RSUs vested, at a reference price of $3.08 per share. After these transactions, he holds 123,431 common shares directly.
ADC Therapeutics director Sandor Victor reported routine equity compensation and related tax withholding. On June 1, 2026, he received 45,000 Common Shares through a grant of restricted stock units under the 2019 Equity Incentive Plan at a stated price of $0.00 per share. These RSUs vest on the earlier of one year from grant or the 2027 Annual Meeting of Shareholders, subject to continued board service. On June 3, 2026, the company withheld 12,600 Common Shares at $3.08 per share to cover his tax obligations upon vesting of previously granted RSUs, a non-market, tax-withholding disposition rather than an open-market sale. After these transactions, Victor directly owns 140,686 Common Shares of ADC Therapeutics.
ADC Therapeutics SA director Viviane Monges reported routine equity compensation and related tax withholding. She was granted 45,000 restricted stock units for her service as a director under the company’s 2019 Equity Incentive Plan, with each unit representing one common share.
In a separate transaction tied to the vesting of previously granted restricted share units, 2,596 common shares were withheld by the company to satisfy her tax withholding obligations at a price of $3.08 per share. After these transactions, she directly owns 186,447 common shares. These events reflect compensation and tax mechanics, not open-market share purchases or sales.
ADC Therapeutics SA director Peter Hug reported routine equity compensation activity. On June 1, 2026, he received a grant of 45,000 Common Shares in the form of restricted stock units (RSUs) under the company’s 2019 Equity Incentive Plan for service as a director.
The RSUs vest on the earlier of one year from the grant date or the date of the 2027 Annual Meeting of Shareholders, subject to his continued service. On June 3, 2026, 2,156 Common Shares were withheld by the company to satisfy his tax withholding obligations upon vesting of previously granted RSUs, a non-market, tax-related disposition rather than an open-market sale.
Following these transactions, Hug directly holds 263,344 Common Shares of ADC Therapeutics SA.
ADC Therapeutics SA director Jean-Pierre Bizzari received an annual grant of 45,000 restricted stock units (RSUs) under the company’s 2019 Equity Incentive Plan for board service. The RSUs vest on the earlier of one year from the grant date or the 2027 annual shareholder meeting, and each RSU converts into one common share.
To cover tax withholding on previously vested RSUs, the company withheld 12,600 common shares at $3.08 per share. After these compensation-related transactions, Bizzari directly holds 139,302 common shares.